Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol-Myers Squibb Avapro

Executive Summary

FDA requests additional information on studies supporting the promotional claim that the highest dose of Avapro (irbesartan, 300 mg once daily) reduces seated trough diastolic blood pressure more than the highest dose (100 mg daily) of Merck's Cozaar (losartan). FDA previously accepted two trials as evidence showing a superior effect for Avapro, however, the agency told Bristol April 6 that, "upon further review," FDA is asking for the protocol and complete set of data files from the "Oparil" study, a description of non-responders who were not titrated to a higher dose of either drug, the bioavailability of both products and an explanation of why there were fewer Avapro-treated patients included in the blood pressure analysis. Bristol submitted a prepublication manuscript for the Oparil trial in response to a March 25, 1998 FDA letter asserting that Bristol was making superiority claims on the basis of one unreplicated study ("The Pink Sheet" June 15, 1998, p. 19)

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts